Abstract
The implementation of therapeutic anticoagulation influences the severity and outcome of patients with coronary artery disease (CAD). This review aims to summarize the current guidelinebased recommendations about the use of new oral anticoagulants (NOACs) in patients with stable CAD (SCAD), acute coronary syndromes (ACS), percutaneous coronary interventions (PCI) and in patients with concomitant atrial fibrillation (AF). The implications of the use of specific NOACs, such as the direct factor Xa inhibitors apixaban and rivaroxaban as well as the direct thrombin inhibitor dabigatran are outlined and compared to the benefits of vitamin k antagonists and antiplatelet agents such as thienopyridines in these settings.
Keywords: Acute coronary syndrome, coronary artery disease, coumadin, novel oral anticoagulation, PCI, vitamin k antagonist, warfarin.
Cardiovascular & Hematological Disorders-Drug Targets
Title:New Oral Anticoagulants in Coronary Artery Disease
Volume: 15 Issue: 2
Author(s): Michael Behnes, Christian Fastner, Uzair Ansari and Ibrahim Akin
Affiliation:
Keywords: Acute coronary syndrome, coronary artery disease, coumadin, novel oral anticoagulation, PCI, vitamin k antagonist, warfarin.
Abstract: The implementation of therapeutic anticoagulation influences the severity and outcome of patients with coronary artery disease (CAD). This review aims to summarize the current guidelinebased recommendations about the use of new oral anticoagulants (NOACs) in patients with stable CAD (SCAD), acute coronary syndromes (ACS), percutaneous coronary interventions (PCI) and in patients with concomitant atrial fibrillation (AF). The implications of the use of specific NOACs, such as the direct factor Xa inhibitors apixaban and rivaroxaban as well as the direct thrombin inhibitor dabigatran are outlined and compared to the benefits of vitamin k antagonists and antiplatelet agents such as thienopyridines in these settings.
Export Options
About this article
Cite this article as:
Behnes Michael, Fastner Christian, Ansari Uzair and Akin Ibrahim, New Oral Anticoagulants in Coronary Artery Disease, Cardiovascular & Hematological Disorders-Drug Targets 2015; 15 (2) . https://dx.doi.org/10.2174/1871529X1502151209111429
DOI https://dx.doi.org/10.2174/1871529X1502151209111429 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effects of Olive Oil on TNF-α and IL-6 in Humans: Implication in Obesity and Frailty
Endocrine, Metabolic & Immune Disorders - Drug Targets Chemical Composition and Biological Effects of Essential Oils from Some Aromatic and Medicinal Plants
The Natural Products Journal Obesity in the Childhood: A Link to Adult Hypertension
Current Pharmaceutical Design TNF-α Inhibitors with Anti-Oxidative Stress Activity from Natural Products
Current Topics in Medicinal Chemistry Single-Pill Triple Fixed Dose Combination Therapy with Single Component Drug Monitoring in Treatment-Resistant Hypertension: A Pilot Study
Current Vascular Pharmacology A More Radical Solution
Reviews on Recent Clinical Trials Prognostic Value of White Blood Cell Counts and C-reactive Protein in Acute Ischemic Stroke Patients After Intravenous Thrombolysis
Current Neurovascular Research Assessing Coronary Blood Flow Physiology in the Cardiac Catheterisation Laboratory
Current Cardiology Reviews Apolipoprotein E Knockout Models
Current Pharmaceutical Design Preface [ Hot Topic: The Physiological and Pharmacological Regulation of Lipid Metabolism (Guest Editor: Dr. Michael E. Pape)]
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents SIRT1, a Calorie Restriction Mimetic, in a New Therapeutic Approach for Type 2 Diabetes Mellitus and Diabetic Vascular Complications
Endocrine, Metabolic & Immune Disorders - Drug Targets Hypertension in Pregnancy: Pathophysiology & Management Strategies
Current Pharmaceutical Design Roles of UDP-Glucuronosyltransferases in Phytochemical Metabolism of Herbal Medicines and the Associated Herb-Drug Interactions
Current Drug Metabolism Therapeutic Proteins and Nanotechnology: Immune Response and Stealth Bioengineered Constructs
Current Drug Metabolism Health Care Discovery, Novo Nordisk A/S, DK-2880 Bagsværd, Denmark
Current Pharmaceutical Biotechnology Recent Updates on Biological Activities of Oxadiazoles
Mini-Reviews in Medicinal Chemistry EDITORIAL [Hot Topic-II: PPAR Ligands and Cardiovascular Disorders: Friend or Foe (Guest Editors: Pitchai Balakumar and Gowraganahalli Jagadeesh)]
Current Molecular Pharmacology Screening for Rare Genetic Variants Associated with Atherosclerosis: Opportunity for Personalized Medicine
Current Vascular Pharmacology Inflammation in Ischemic Stroke Subtypes
Current Pharmaceutical Design Statins as Anti-Inflammatory Agents in Atherogenesis: Molecular Mechanisms and Lessons from the Recent Clinical Trials
Current Pharmaceutical Design